Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis
Sponsor: European and Developing Countries Clinical Trials Partnership (EDCTP)
This PHASE2 trial investigates Tuberculosis, Pulmonary and is currently completed. European and Developing Countries Clinical Trials Partnership (EDCTP) leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Mar 2022 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- German Federal Ministry of Education and Research
- Medical Research Council
- Michael Hoelscher
- Radboud University Medical Center
- Sequella, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .